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Abstract
Despite its limitations, ultrasound-guided biopsy is still the “gold standard”
for the diagnosis of prostate cancer (PCa). Multiparametric magnetic resonance
imaging (mp-MRI) plays an increasingly important role in patients with prior
negative biopsy; several studies report an improved clinically significant prostate
cancer (Cs PCa) detection rate for MRI-targeted biopsy compared to the standard
biopsy. There are currently three techniques for the MRI-targeted biopsy: the
cognitive registration, the software-assisted fusion registration, and the in-bore
biopsy. The best MRI-targeted biopsy technique is still a matter of debate in
literature; however, MRI/TRUS fusion-guided biopsy is often described as the
most accurate and cost-effective approach; we describe the technique and
its results.
Keywords: fusion biopsy, prostate cancer, prostate biopsy, prostate
magnetic resonance, PI-RADS score
1. Introduction
Prostate cancer is the most common cancer expected to occur in men,
accounting for 19% of the new cancer cases diagnosed worldwide [1, 2].
Currently, the only way to make a definitive diagnosis of prostate cancer is
considered to be the prostate biopsy and the subsequent histopathological exami-
nation. For many years, the transrectal ultrasound (TRUS)-guided biopsy has
been considered the gold standard in the diagnosis of prostate adenocarcinoma.
This standard technique makes use of random 12-cores to sample the entire
prostate gland [3].
The criteria for submitting patients to prostate biopsy are either a persistently
elevated/rising prostate-specific antigen (PSA) level or an abnormal digital rectal
examination (DRE). Prostate biopsy may also be recommended on the basis of the
pathologic results of previous biopsy specimens: men who are found to have a high-
grade prostatic intraepithelial neoplasia (HG-PIN), atypical small acinar prolifera-
tion (ASAP), or low-risk prostate cancer should be subjected to a follow-up biopsy
[2]. The TRUS-guided biopsy has significant limitations; several nonmalignant
conditions of the prostate (such as inflammation, prostatitis, and benign prostatic
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hyperplasia) can appear hypoechoic, and some carcinoma can appear isoechoic [4].
A cancer detection rate (DR) of 33–57% can be achieved with the standard biopsy,
and following the first negative biopsy, the detection rate decreases further [5].
Furthermore, the standard biopsy may lead to an underdiagnosis of clinically sig-
nificant prostate cancers, missing 50–80% of cases [6]. The multiparametric mag-
netic resonance imaging plays nowadays an increasingly important role in the
diagnostic approach to prostate cancer. It provides anatomic and functional images
allowing detection and localization of the suspicious lesions that could harbor
prostate cancer.
Several studies indicate that the MRI-targeted biopsy approach improves the
overall and clinically significant PCa detection rate. It also strongly reduces the
number of clinically insignificant prostate cancers diagnosed, therefore preventing
overtreatment.
According to the European Association of Urology (EAU) guidelines, an mp-
MRI evaluation and a subsequent MRI-targeted biopsy should be recommended for
patients with persistent clinical suspicion of prostate cancers even if a previous
standard biopsy has provided negative results. Based on the guideline recommen-
dations, if the targeted and standard biopsies are used in conjunction, significantly
better results can be achieved [7].
The role of mp-MRI in the diagnostic pathway of biopsy-naïve patients is instead
still a matter of debate.
2. Technology and techniques
2.1 Interpretation and reporting of multiparametric MRI
The magnetic resonance imaging (MRI) has been used for locoregional staging
in patients with proven prostate cancers since the 1980s [8]. The multiparametric
protocol has been introduced to discriminate nonmalignant tissue and potentially
cancerous lesions. Since its introduction, the field of PCa diagnosis has been
revolutionized.
According to the European Society of Urogenital Radiology (ESUR) guidelines,
the multiparametric MRI protocol should include three MRI modalities: triplanar
T2-weighted (T2W) sequences, axial diffusion-weighted imaging (DWI) with
apparent diffusion coefficient (ADC) mapping, and dynamic contrast-enhanced
images (DCE) [8, 9].
To standardize the evaluation and reporting of prostate mp-MRI examinations, a
consensus-based guideline, known as Prostate Imaging Reporting and Data System
(PI-RADS) version 1, was introduced in 2012. Most recently, a revised version of
the document (PI-RADS v2) was published.
One of the main aims of the PI-RADS v2 document was to develop categories
summarizing the levels of suspicion; each detected lesion in the prostate gland
is assigned a score that goes from 1 to 5. The 5-point scoring, based on the like-
lihood that MRI findings correlate with the presence of Cs PCa, is defined as
follows:
1. very low risk (clinically significant PCa is highly unlikely to be present)
2. low risk (clinically significant PCa is unlikely to be present)
3. intermediate risk (the presence of clinically significant PCa is equivocal)
2
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4.high risk (clinically significant PCa is likely to be present)
5. very high risk (clinically significant PCa is highly likely to be present)
According to PI-RADS v2, a cancer is considered to be clinically significant when
Gleason score (GS) >7, and/or tumor volume >0.5 ml, and/or an extraprostatic
extension is diagnosed [8, 9].
A meta-analysis related to the diagnostic accuracy of PI-RADS v2 shows that the
PCa detection sensitivity is 0.85 and the specificity is 0.71 [10].
The most significant difference between PI-RADS v1 and PI-RADS v2 is that
DWI and T2W are used as the primary determining sequences, respectively, for
peripheral zone (PZ) and transitional zone (PZ) (refer to Tables 1 and 2), while
DCE plays a limited role in the detection of PZ lesions classified as PI-RADS 3.
Likewise, when a TZ lesion has a T2W score 3, DWI may increase the likelihood
that the finding corresponds to a score 4.
Another significant difference is that a size criterion (smaller or larger than
1.5 cm) is taken into account by PI-RADS v2 to differentiate score 4 from 5 in
both the peripheral and transitional zones. Moreover, a 39-sector map has been
introduced to locate the suspicious findings [8, 9]. This has led to an improvement
of the interdisciplinary communications between radiologists and urologists.
Following the PI-RADS score assignment to the suspicious lesion, the region of
interest (ROI) detected through mp-MRI can be biopsied to confirm the diagnosis.
DWI
score
Peripheral zone lesion PI-RADS category
1 No abnormality on ADC and high b-value DWI 1
2 Indistinct hypointense on ADC 2
3 Focal mildly/moderately hypointense on ADC and isointense/mildly
hyperintense on high b-value DWI
3 if DCE is negative
4 if DCE is positive
4 Focal markedly hypointense on ADC and markedly hyperintense on
high b-value DWI; <1.5 cm in greatest dimension
4
5 Same as 4, but >1.5 cm in greatest dimension or definite
extraprostatic extension/invasive behavior
5
Table 1.
PI-RADS v2 categories assignment to peripheral zone lesions based on the scoring of DWI sequence.
T2W
score
Transition zone lesion PI-RADS category
1 Homogeneous intermediate signal intensity (normal) 1
2 Circumscribed hypointense or heterogeneous encapsulated nodules 2
3 Heterogeneous signal intensity with obscured margins
Includes others that do not qualify as 2, 4, or 5
3 if DWI score is <4
4 if DWI score is 5
4 Lenticular or noncircumscribed, homogeneous, moderately
hypointense, and <1.5 cm in greatest dimension
4
5 Same as 4, but >1.5 cm in greatest dimension or definite
extraprostatic extension/invasive behavior
5
Table 2.
PI-RADS v2 categories assignment to transitional zone lesions based on the scoring of T2W sequence.
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Several studies recommend that the MRI-targeted biopsy be performed for
findings classified as PI-RADS 4 and 5 [11–13]. According to the ESUR guidelines,
biopsy for PI-RADS 3 lesions may or may not be appropriate. Clinical factors should
be considered for lesions pertaining to this category. For findings with PI-RADS
1 or 2, biopsy is not recommended [8, 9].
2.2 Methods of MRI-targeted biopsy
There are currently three techniques for the MRI-targeted biopsy: the
cognitive registration, the software-assisted fusion registration and the in-bore
biopsy [14–17]. This paragraph provides an overview of the pro and cons of these
techniques (Table 3).
In the cognitive registration, also known as visual registration, a prebiopsy
mp-MRI is performed to localize the suspicious lesions. The targeted biopsy is then
performed using TRUS guidance with the objective of estimating the area where
the lesion is [14, 15].
Despite its low cost, the cognitive registration technique is strictly operator-
dependent and is more prone to errors when compared to the other techniques.
In addition, with this technique it is not possible to track the location of each
biopsy core [15, 18].
In the software-assisted fusion registration, known as MRI/TRUS fusion-guided
biopsy, the region of interest is identified in the mp-MRI images. Through a specific
software platform, the MRI images are fused with the real-time ultrasound
images [14, 17, 19].
The targeted prostate biopsy based on mp-MRI and TRUS imaging combine the
advantages of both techniques, i.e., the superior sensitivity of MRI for targeting
suspicious lesions and the practicality of TRUS [5, 18]. The greater reproducibility,
high precision, and lower operator dependence represent some of the main
advantages of the MRI/TRUS fusion-guided biopsy [17].
Various fusion platforms are currently registered by the Food and Drug Admin-
istration (FDA), which differ with respect to image registration (rigid or elastic),
tracking (electromagnetic tracking, mechanical position encoders, and image-based
software tracking) and biopsy approaches (transrectal or transperineal) [19].
In our institution the MRI/TRUS fusion-guided biopsy is performed in an
outpatient setting; we use the BioJet system (DK Technologies GmbH) which is
one of the most approved systems by the FDA [19] (Figure 1).
Techniques Advantages Disadvantages
Cognitive registration • Low cost
• Additional training not
required
• Operator-dependent
• Less accurate
MRI/TRUS fusion-guided
biopsy
• High precision
• Less operator-dependent
• Additional software platform required
• Specialized operators required
In-bore biopsy • High precision • Few sampled cores can be taken
• Specialized MRI equipment and
operators required
• High cost
• Long time required
Table 3.
Comparison between the three techniques for the MRI-targeted biopsy.
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T2 traversal MRI images are used to contour the prostate and the lesions; then,
the system fuses the marked MRI images with live transrectal ultrasound on both
the axial and sagittal image planes to guarantee the best needle placement.
During the biopsy procedure, the TRUS probe is fixed to a stepper provided with
position sensors that transmit the exact position of the probe to the software.
The location of biopsy cores can be tracked and recorded on a 3D map of the
prostate, and a report of the cores collected is provided at the end of the procedure;
it guarantees reproducible re-biopsies which is a very important advantage
particularly for patients in active surveillance (Figures 2–5).
The system supports both transrectal and transperineal biopsies depending on
the surgeon preference; the transperineal route with patients placed in lithotomy
position is our preferred approach. All biopsy samples are obtained after a local
anesthesia with 2% lidocaine and ropivacaine. At least three biopsy cores from each
lesion are taken. Standard 12-core biopsies from the lateral and medial aspects of the
base, mid, and apical prostate are taken during the same procedure.
With the in-bore biopsy technique the target lesion is biopsied with the patient
placed in a fixed position inside the mp-MRI scanner.
Unlike the MRI/TRUS fusion-guided biopsy, the in-bore biopsy procedure is
performed and tracked under MRI fluoroscopy guidance; real-time ultrasound
images are not used. A transrectal, transperineal or transgluteal approach can be
used during the in-bore biopsy [14, 15].
One of the main advantages of this technique is the high precision of the
targeted cores as the high-quality MRI images provide a visual feedback of the
biopsy needle localization [12, 15, 16]. However, the significant time required in the
MRI scanner and the availability of specialized MRI equipment make the costs
associated with this technique higher than the others [14–16].
Even if the determination of the most effective MRI-targeted biopsy technique is
still a matter of debate in literature, some authors have concluded that the MRI/
Figure 1.
Biojet system.
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TRUS fusion-guided biopsy is much more accurate and cost-effective than the other
techniques [3, 14, 20–22].
Oberlin et al. have recently compared the MRI/TRUS fusion biopsy with the
cognitive approach. About 231 patients have been enrolled in the study. The study
shows that the targeted biopsy has a greater overall detection rate for prostate
cancer (48.1 vs. 34.6%) and clinically significant PCa when compared with cogni-
tive registration [20]. Similar results were obtained by Cool that performed a study
on 100 patients with the objective of comparing targeted biopsy accuracies of
cognitive registration using 2D or 3D TRUS guidance with MRI/TRUS fusion
biopsy. The detection rate of cognitive registration, with both 2D and 3D TRUS
probe, appears to be lower than that achieved through the MRI/TRUS fusion
biopsy, with less than 50% of the clinically significant PCa successfully sampled (48
and 45%, respectively, for 2D and 3D TRUS). Even when the Cs PCa is successfully
Figure 2.
Lesions contour.
Figure 3.
Fusion process trasverse.
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sampled by cognitive registration, the percentage of cancerous tissue detected by
the MRI/TRUS fusion biopsy in each biopsy core was significantly higher [21].
A randomized trial was carried out on 210 patients to compare the MRI/TRUS
fusion biopsy and the in-bore technique [23]. No significant difference in the
overall and Cs PCa detection rates was observed between the two groups; the first
constituted of 104 patients that were subjected to fusion biopsy (39 and 32%,
respectively, for the PCa and Cs PCa detection rate), while an in-bore biopsy was
performed on the other 106 patients (37 and 29%, respectively, for the PCa and Cs
PCa detection rate). This is in agreement with the study performed by Vanderink
et al. according to which there is no significant difference in the detection rate
between the two biopsy techniques [24].
It should be noted however that, due to its significant costs, the in-bore
technique is less commonly adopted than visual registration and fusion biopsy.
Figure 5.
Biopsy.
Figure 4.
Fusion process sagittal.
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2.3 Route of biopsy
The route of prostate biopsy (transrectal, transperineal, or transgluteal) may
differ between the various operators, but the transrectal (TR) and transperineal
(TP) are the two primary approaches through which the prostate tissue can be
taken [15, 16].
The TP biopsy is performed with the patient in the lithotomy position with the
needle passing through the perineum skin; the TR biopsy is instead performed in
the left lateral decubitus with the knees and hips flexed 90° and the needle passing
through the anterior rectal wall [25].
Both the TP and TR biopsies are very effective in diagnosing PCa and provide a
superimposable detection rate. However, the TP approach allows a better sampling
of the lesions located in the anterior part of the gland, therefore resulting in a
greater percentage of PCa of the anterior zone compared with the TR approach
(86.7 vs. 46.7%) [26, 27].
Even if there is no significant difference between the TP and TR biopsies in
terms of the overall complication rate, rectal bleeding and infection-related com-
plications are more frequently observed when adopting the TR approach [25, 26,
28, 29]. As the access to the prostate is via the rectal mucosa, the TR biopsy
increases the likelihood of introducing rectal flora into the urinary tract and the
blood circulation. Most of the reported infections result from Escherichia coli [29].
The overall risk of infectious complications, including bacteriuria, bacteremia,
fever, urinary tract infections and sepsis may be up to 6.3% [15, 28].
The likelihood of infections may be reduced by adopting the TP biopsy approach
[15, 28]. To further minimize infectious complications, patients are required to have
antibiotic prophylaxis [28].
According to the EAU guidelines, quinolones are recommended as the first-line
option: ciprofloxacin is prescribed in more than 90% of cases. Although no different
outcomes were observed between oral and systemic administration, a single oral
dose is usually preferred. In the event of antimicrobial resistance to quinolones,
alternative antibiotics of choice are cephalosporins and aminoglycosides [28].
On the other hand, pain management is more challenging with the TP approach
[26]. The average VAS score, used to measure the symptom severity and pain
control, is higher than that related to the TR biopsy. To ensure pain control, the TP
biopsy is usually performed under local anesthesia of both the perineum skin and
the periprostatic region [25, 26, 29].
Another issue to consider is that the TP-targeted biopsy is a relatively complex
procedure requiring a longer learning curve.
In conclusion, the choice of the biopsy method depends on several factors, such
as lesion localization, patients’ risk factors, operators’ preference, and technique
availability.
3. Outcomes
3.1 Overall results
Urologists frequently face the dilemma of patients with a negative prostate
biopsy and an elevated PSA value or a suspicious digital rectal examination
(DRE) [2].
Prior to the introduction of the MRI/TRUS fusion biopsy, patients with negative
TRUS-guided biopsies were regularly subjected to multiple biopsy procedures. This
approach resulted in a higher detection rate of insignificant low-grade tumors,
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therefore increasing overtreatment. The MRI/TRUS fusion biopsy is considered to
be a significant enhancement through which the weaknesses of the systematic
random biopsy can be overcome. Through the use of the mp-MRI for the identifi-
cation of suspicious lesions and the execution of the subsequent targeted biopsy, a
greater number of prostate cancers can be detected [3, 6, 30–34].
The most significant strength of the targeted biopsy, when compared to the
standard technique, is related to its improved detection capability of Cs PCas
needing a definitive treatment. Another advantage relates to the possibility of
avoiding biopsy for patients with a normal mp-MRI therefore reducing the detec-
tion of clinically insignificant cancers and preventing overtreatment of indolent
tumors.
A summary of the results in terms of the overall and Cs PCa detection rates in
the available literature is provided in Table 4. The systematic review performed by
Valerio et al. is aimed to compare the standard and MRI/TRUS fusion biopsy in
terms of detection rate and efficiency [3]. The overall detection rate reported is 43.4
and 50.5%, respectively, whereas the detection rate for clinically significant PCa is
23.6 and 33.3%, respectively. The above study also shows that a considerable num-
ber of Cs PCas can be detected only if a targeted biopsy is performed, particularly if
the anatomical locations of cancer are the transition zone and the anterior
fibromuscular stroma [35].
Moreover, according to Valerio et al., fewer core samples (9.2 vs. 37.2%) are
required to detect the same number of clinically significant cancers making the
targeted approach less uncomfortable for patients [3].
In another study involving more than 1000 patients, Siddiqui et al. show that the
standard and targeted biopsies have diagnosed a similar number of prostate cancers
(469 vs. 461). The significant difference highlighted is that the MRI/TRUS fusion
biopsy has diagnosed a greater percentage (+30%) of high-risk cancers and a lower
percentage (17%) of low-risk cancers than the standard biopsy [30]. Similar
results were obtained by other recent studies [12, 13, 35–37].
However, the diagnostic accuracy of the MRI/TRUS fusion-guided biopsy does
not allow the prostate standard biopsy to be avoided: the combined execution of the
standard and targeted biopsy will result in the detection of a greater number of PCa
cases [30, 36, 38].
The most significant predictive factor for the detection of prostate cancers
through the targeted biopsy is the ROI grade. As several studies have demonstrated,
the likelihood of diagnosing clinically significant PCas increases with the PI-RADS
score, i.e., the greater is the PI-RADS score, the higher is the probability of detecting
PCas [12, 13, 36, 37, 39, 40].
The study performed by Borkowetz et al., including 625 patients subjected to
standard and MRI/TRUS fusion-guided biopsies, shows that PCa was detected in
20, 33 and 70% of patients with PI-RADS 3, 4 and 5 lesions, respectively [37].
These results are consistent with the data recently published by Kasivisvanathan
and Cash [13, 39]. In particular, the Cs PCa detection rates resulting from the latter
study were 16.8, 46.1 and 84.7%, respectively, for PI-RADS categories 3, 4 and 5
[39]. Based on the above, the ESUR guidelines recommend that an MRI-targeted
biopsy be performed in patients with PI-RADS 4 and 5 lesions [8, 9]. The manage-
ment of PI-RADS 3 lesions still remains a challenge. An mp-MRI presenting PI-
RADS 3 lesions should be assessed considering clinical parameters such as PSA
density (PSAD) and total PSA value [36, 33]. An increased PSA density, i.e., the
PSA level related to the total prostate volume, is considered to be the most signifi-
cant clinical predictive factor for prostate cancers. Some studies recommend that
the patient should be subjected to targeted biopsy if the PSA density
>0.10 ng/ml/cc [33].
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Method Study Definition for Cs PCa Sample
size
Overall
DR
DR Cs PCa DR PI-RADS 3
(Cs PCa)
DR PI-RADS 4
(Cs PCa)
DR PI-RADS 5
(Cs PCa)
Cognitive registration Puech et al. [51] GS ≥ 3 + 4 95 47% NR NR NR NR
Delongchamps
et al. [52]
CCL ≥ 5 mm or GS ≥ 3 + 4 127 74.1% NR NR NR NR
Wysock et al. [53] GS ≥ 3 + 4 125 26.7% 15.1% NR NR NR
Cool et al. [21] GS ≥ 3 + 4 or tumor involvement in
the core >50%
100 NR 48% (2D TRUS) 45%
(3D TRUS)
NR NR NR
Oberlin et al. [20] GS ≥ 3 + 4 150 34.6% 16.7% NR NR NR
John et al. [22] GS ≥ 3 + 4 131 NR 17.6% 40.7% (11.1%) 67.9% (42.9%) 69.5% (35.6%)
Osses et al. [54] GS ≥ 3 + 4 64 56.2% NR 16.7% 68.7% 95.2%
In-bore biopsy Pokorny et al.
[55]
NR 142 56.4% NR 10.5% 69.9%
Kaufmann et al.
[56]
GS ≥ 3 + 4, PSA >10 ng/ml and PSAD
>0.15 ng/ml/cm3
35 46% 46% NR NR NR
Quentin et al. [57] CCL > 5 mm or GS ≥ 3 + 4 128 53.1% 45.3% NR NR NR
Arsov et al. [23] GS ≥ 3 + 4 106 37% 29% NR NR NR
Penzkofer et al.
[58]
GS ≥ 3 + 4 87 56.7% 27.8% NR NR NR
Felker et al. [59] GS ≥ 3 + 4 461 37.3% 27.9% 16.4% (10.4%) 57.8% (42.7%) 96.3% (84%)
Schimmoller et al.
[60]
GS ≥ 3 + 4 148 49.8% 41.1% NR NR NR
Tan et al. [61] GS ≥ 3 + 4 106 53.7% 36.6% 19.4% (9.7%) 78% (54%) 82.8% (62.1%)
Vanderink et al.
[24]
GS ≥ 3 + 4 227 85% 61.2% NR 72.7% (49.4%) 91.3% (67.3%)
Osses et al. [54] GS ≥ 3 + 4 155 64.5% NR 10.3% 77.4% 88.9%
10 M
a
le
R
ep
rod
u
ctive
H
ea
lth
Method Study Definition for Cs PCa Sample
size
Overall
DR
DR Cs PCa DR PI-RADS 3
(Cs PCa)
DR PI-RADS 4
(Cs PCa)
DR PI-RADS 5
(Cs PCa)
MRI/TRUS fusion-
guided biopsy
Kuru et al. [62] NCCN criteria 347 50.6% 41.1% NR NR NR
Rastinehad et al.
[63]
Epstein criteria 105 50.5% 44.8% NR NR NR
Wysock et al. [53] GS ≥ 3 + 4 125 32% 20.3% NR NR NR
Sonn et al. [18] CCL ≥ 4 mm or GS ≥ 3 + 4 105 34% 25% NR NR NR
Valerio et al. [3] NR 2293 50.5% 33.3% NR NR NR
Shoji et al. [64] CCL > 4 mm or GS ≥ 3 + 4 20 31.8% NR 13.3% 33.3% 88.9%
Junker et al. [34] NR 50 46% NR 28.6% 54.3% 100%
Borkowetz et al.
[31]
Epstein criteria 263 44.1% 35.7% 24.2% 41.6%
Mozer et al. [46] CCL > 4 mm or GS ≥ 3 + 4 152 53.9% 43.4% NR NR NR
Siddiqui et al.
[30]
NR 1003 46% 37.5% NR NR NR
Salami et al. [35] Epstein criteria 140 52.1% 47.9% 26.7% 66.7% 95.8%
Oberlin et al. [20] GS ≥ 3 + 4 81 48.1% 28.6% NR NR NR
Cash et al. [39] CCL ≥ 4 mm or GS ≥ 3 + 4 408 56% NR 26% (16.8%) 62% (46.1%) 89% (84.7%)
Filson et al. [36] GS ≥ 3 + 4 1042 43.6% 27.8% NR (16%) NR (33%) NR (69%)
Borkowetz et al.
[37]
GS ≥ 3 + 4 625 43% 34% 20% (12%) 33% (27%) 70% (61%)
Tan et al. [33] GS ≥ 3 + 4 115 35.7% 30.4% 21.4% (15.7%) 52.9% (47.1%) 72.7% (72.7%)
Hansen et al. [65] GS ≥ 3 + 4 487 51.1% 30.6% 43.7% (19.5%) 58% (32%) 82.6% (70.4%)
Osses et al. [32] GS ≥ 3 + 4 664 64.5% 40.6% 10.3% (3.5%) 77.3% (45.2%) 88.9% (66.7%)
Boesen et al. [12] Epstein criteria 206 33.8% 26.4% 22.2% 62.7% 94.1%
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Method Study Definition for Cs PCa Sample
size
Overall
DR
DR Cs PCa DR PI-RADS 3
(Cs PCa)
DR PI-RADS 4
(Cs PCa)
DR PI-RADS 5
(Cs PCa)
Porpiglia et al.
[44]
Epstein criteria 212 60.5% 56.8% 12.5% (12.5%) 80% (75%) 87.5% (81.3%)
Hofbauer et al.
[40]
GS ≥ 3 + 4 704 63% 45% 39% (23%) 72% (49%) 91% (77%)
Kasivisvanathan
et al. [13]
GS ≥ 3 + 4 252 47% 38% 34% (12%) 69% (60%) 94% (83%)
Our results Epstein criteria 352 50.9% 36.5% 38.2% (15.9%) 63.7% (44.9%) 86.5% (74.2%)
MRI, magnetic resonance imaging; Cs PCa, clinically significant prostate cancer; DR, detection rate; PI-RADS, prostate imaging reporting and data system; GS, Gleason score; NR, not reported; CCL,
maximum cancer core length; PSA, prostate-specific antigen; PSAD, prostate-specific antigen density; NCCN, National Comprehensive Cancer Network.
Table 4.
Biopsy procedure results published in literature.
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Another issue to consider is that, prior to the introduction of the MRI/TRUS
fusion biopsy, literature did not describe a strong concordance between biopsy and
radical prostatectomy Gleason score (GS). A significant pathological GS (pGS)
upgrading, when compared with that of standard biopsy specimens (bGS), was
observed in 50% of patients, while up to 80% of patients were downgraded [41, 42].
As the GS is a significant decision-making tool for patient treatment, its correct
attribution is absolutely essential [2, 41].
With the introduction of the MRI/TRUS fusion biopsy, a high consistency
between bGS and pGS has been achieved. Its accuracy in predicting the
pathological GS allows minimizing the risk of possible cancer upgradings or
downgradings [37, 42].
The MRI/TRUS fusion biopsy superior performance has been demonstrated by
Porpiglia. About 246 patients subjected to robot-assisted RP were enrolled. For
91.5% of patients the anatomopathological results of surgical specimens were con-
sistent with those achieved through biopsy cores. Also, with the targeted biopsy,
the GS upgrading and downgrading was 7.8 and 0.8%, respectively, significantly
lower than the rates achieved with the standard biopsy (39.3 and 6.8%,
respectively) [42].
3.2 Naïve-biopsy patients
The current guidelines of the European Association of Urology and National
Institute for Health and Care Excellence (NICE) recommend that an mp-MRI
evaluation and a subsequent targeted biopsy be performed in patients with a per-
sistent clinical suspicion of PCa (elevated PSA level and/or abnormal DRE) after a
previous negative biopsy [7, 43].
The use of mp-MRI as the primary diagnostic tool for biopsy-naïve patients is
controversial. However, recent studies support the excellent performance of mp-
MRI in the detection of PCa in biopsy-naïve patients [30, 38, 44–46].
A clinical trial was recently performed with 212 biopsy-naïve patients randomly
assigned to either the targeted or the standard biopsy group. Results shows that
targeted biopsy provides a greater detection rate for both PCa (50.5 vs. 29.5%) and
clinically significant PCa (43.9 vs. 18.1%) [44]. These results agree with those
achieved by a multicentric trial involving 214 biopsy-naïve patients with at least one
suspicious lesion detected through mp-MRI [38].
Although further confirmation is required, men who have never been biopsied
before may benefit from the use of mp-MRI as a preliminary test. In case of a
positive MRI, the combined execution of MRI/TRUS fusion and standard biopsies
would then be recommended and improve the detection of CsPca [38, 45].
A critical issue to consider are the economic resources required if the MRI were
used as the primary diagnostic tool in all patients with clinical suspicious of PCa.
Nevertheless, recent analyses have shown that mp-MRI for the initial detection
of PCa appears to be cost-effective when compared with repeated standard
biopsies [38, 45].
3.3 Patients on active surveillance
Active surveillance (AS) is the strategy of choice in men with localized and very
low/low-risk prostate cancer to avoid or delay treatment that might not be imme-
diately necessary [47–49].
Even if there is still no definitive agreement with regard to the selection criteria
for AS candidates, a widely accepted criteria is based on the following: clinical T1c
or T2a, PSA <10 ng/ml, fewer than two to three positive cores with <50% cancer
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involvement of every positive core, and GS 3 + 3 [7]. Patients fulfilling this criteria
may benefit from AS, reducing treatment-related complications without
compromising their survival.
AS consists of a close disease monitoring through clinical and histological
parameters: commonly used tools are serial PSA measurements, DRE, and repeat
biopsies [2, 7]. If biochemical or histological evidence of cancer progression is
observed, a radical treatment will then be proposed [2, 47, 48].
The main limitation associated with the AS protocol is the risk of
underestimating the extent and aggressiveness of prostate cancer. Some authors
have reported that TRUS-guided biopsies may lead to an underestimation in one
third of cases [47, 48, 50].
mp-MRI is currently emerging as a significant diagnostic tool through which the
above risk can be minimized. It can be used in one of the three following stages: at
the time of initial diagnosis of men with low-risk cancer, before confirmatory
biopsy and during follow-up [49].
At the time of initial diagnosis, the mp-MRI is much more accurate in the
identification and characterization of prostate cancers, resulting in a more accurate
patients enrollment for the AS protocol. Its use is recommended to rule out signif-
icant PCas that were missed by the initial biopsy.
Before the confirmatory biopsy, usually performed within the first year from the
initial diagnosis, the mp-MRI can reveal the need to perform a targeted biopsy in
addition to the commonly adopted standard biopsy. The combined use of these two
techniques may lead to a more accurate evidence of disease progression [47–49].
This is in line with the review performed by Schoots et al. [48] according to which
the combined execution of targeted and standard biopsies resulted in 27% cancer
upgrading. It is therefore recommended that both biopsy techniques be adopted at
the stage of the confirmatory biopsy [48, 49].
During the follow-up period, a yearly mp-MRI might allow the annual biopsy to
be avoided for those patients with stable MRI findings. The repeat biopsy should be
performed only in the event that a disease progression is detected by the mp-MRI
[47]. It should be noted however that there is still no definitive agreement on the
use of the mp-MRI as a replacement for the repeat biopsy during the follow-up
period [49].
Key points
• For many years the TRUS-guided biopsy has been considered as the gold
standard in the diagnosis of PCa. Even if the ultrasound-based imaging is a
great tool for guiding a biopsy needle, it cannot identify regions of interest that
could harbor PCa in all cases. This is the reason why in the last decade, the
research activities have focused on the development of imaging methods that
can differentiate between noncancerous tissue and malignant lesions with
greater accuracy.
• The introduction of mp-MRI as an imaging modality for the detection and
localization of regions of interest has nowadays revolutionized the way through
which PCa is managed and treated. According to the ESUR guidelines, the mp-
MRI protocol should include T2W, DWI, and DCE sequences.
• PI-RADS v2 was introduced by the ESUR to standardize the evaluation and
reporting of mp-MRI examinations. This 5-point scoring system is based on the
likelihood that MRI findings correlate with the presence of Cs PCa.
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• According to the EAU guidelines, an mp-MRI followed by an MRI-targeted
biopsy should be recommended for patients with persistent clinical suspicion
of prostate cancer (elevated PSA level and/or abnormal DRE) after a previous
negative standard biopsy.
• mp-MRI is currently emerging as a significant diagnostic tool in patients on
active surveillance protocol both for the enrollment of patients with low-risk
indolent disease and before the confirmatory biopsy.
• The role of mp-MRI in the management of biopsy-naïve patients is still a
matter of debate. However, its diagnostic accuracy is such that recent studies
support the use of mp-MRI as a preliminary test in patients with no prior
biopsies.
• The cognitive registration, software-assisted fusion registration, and in-bore
biopsy are the techniques currently available for the MRI-targeted biopsy. The
MRI/TRUS fusion-guided biopsy appears to be the most accurate and cost-
effective approach when compared with other biopsy procedures.
• A greater number of prostate cancers can be diagnosed through the MRI-
targeted biopsy, resulting in an increased overall detection rate. The great
advantage of this technique is that it increases the detection rate of Cs PCas,
reducing the detection of clinically insignificant cancers.
• The MRI-targeted biopsy has been shown to be more accurate in predicting the
pathological GS, providing a strong consistency between bGS and pGS. The
rate of a possible cancer underestimation or overestimation is therefore
minimized.
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